CN101861331B - 垂枝桦花粉主要变应原的低变应原性变体 - Google Patents
垂枝桦花粉主要变应原的低变应原性变体 Download PDFInfo
- Publication number
- CN101861331B CN101861331B CN200880116680.6A CN200880116680A CN101861331B CN 101861331 B CN101861331 B CN 101861331B CN 200880116680 A CN200880116680 A CN 200880116680A CN 101861331 B CN101861331 B CN 101861331B
- Authority
- CN
- China
- Prior art keywords
- gly
- seq
- bet
- ser
- lys
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000013566 allergen Substances 0.000 title claims abstract description 25
- 241000219430 Betula pendula Species 0.000 title claims abstract description 14
- 230000000774 hypoallergenic effect Effects 0.000 title abstract 2
- 235000009109 Betula pendula Nutrition 0.000 title description 12
- 208000026935 allergic disease Diseases 0.000 claims abstract description 13
- 238000011282 treatment Methods 0.000 claims abstract description 7
- 230000001225 therapeutic effect Effects 0.000 claims abstract 2
- 108090000623 proteins and genes Proteins 0.000 claims description 19
- 102000004169 proteins and genes Human genes 0.000 claims description 19
- 241000196324 Embryophyta Species 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 230000009257 reactivity Effects 0.000 claims description 8
- 229960005486 vaccine Drugs 0.000 claims description 8
- 230000002009 allergenic effect Effects 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 5
- 102000039446 nucleic acids Human genes 0.000 claims description 5
- 150000007523 nucleic acids Chemical class 0.000 claims description 5
- 125000000539 amino acid group Chemical group 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims description 2
- 208000002205 allergic conjunctivitis Diseases 0.000 claims description 2
- 208000024998 atopic conjunctivitis Diseases 0.000 claims description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 102000003916 Arrestin Human genes 0.000 description 28
- 108090000328 Arrestin Proteins 0.000 description 28
- 210000002966 serum Anatomy 0.000 description 25
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 15
- CQZDZKRHFWJXDF-WDSKDSINSA-N Gly-Gln-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CN CQZDZKRHFWJXDF-WDSKDSINSA-N 0.000 description 12
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 230000008859 change Effects 0.000 description 11
- 238000011534 incubation Methods 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 125000003275 alpha amino acid group Chemical group 0.000 description 7
- 229940024606 amino acid Drugs 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 230000008034 disappearance Effects 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- MVBWLRJESQOQTM-ACZMJKKPSA-N Ala-Gln-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O MVBWLRJESQOQTM-ACZMJKKPSA-N 0.000 description 6
- ZVFVBBGVOILKPO-WHFBIAKZSA-N Ala-Gly-Ala Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O ZVFVBBGVOILKPO-WHFBIAKZSA-N 0.000 description 6
- LNNSWWRRYJLGNI-NAKRPEOUSA-N Ala-Ile-Val Chemical compound C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O LNNSWWRRYJLGNI-NAKRPEOUSA-N 0.000 description 6
- GWIJZUVQVDJHDI-AVGNSLFASA-N Asp-Phe-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O GWIJZUVQVDJHDI-AVGNSLFASA-N 0.000 description 6
- WDQXKVCQXRNOSI-GHCJXIJMSA-N Cys-Asp-Ile Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WDQXKVCQXRNOSI-GHCJXIJMSA-N 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- OIIIRRTWYLCQNW-ACZMJKKPSA-N Gln-Cys-Asn Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O OIIIRRTWYLCQNW-ACZMJKKPSA-N 0.000 description 6
- XKPACHRGOWQHFH-IRIUXVKKSA-N Gln-Thr-Tyr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O XKPACHRGOWQHFH-IRIUXVKKSA-N 0.000 description 6
- KKCUFHUTMKQQCF-SRVKXCTJSA-N Glu-Arg-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O KKCUFHUTMKQQCF-SRVKXCTJSA-N 0.000 description 6
- CQAHWYDHKUWYIX-YUMQZZPRSA-N Glu-Pro-Gly Chemical compound OC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O CQAHWYDHKUWYIX-YUMQZZPRSA-N 0.000 description 6
- NNQDRRUXFJYCCJ-NHCYSSNCSA-N Glu-Pro-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O NNQDRRUXFJYCCJ-NHCYSSNCSA-N 0.000 description 6
- QGZSAHIZRQHCEQ-QWRGUYRKSA-N Gly-Asp-Tyr Chemical compound NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 QGZSAHIZRQHCEQ-QWRGUYRKSA-N 0.000 description 6
- VAXIVIPMCTYSHI-YUMQZZPRSA-N Gly-His-Asp Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)CN VAXIVIPMCTYSHI-YUMQZZPRSA-N 0.000 description 6
- ITZOBNKQDZEOCE-NHCYSSNCSA-N Gly-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)CN ITZOBNKQDZEOCE-NHCYSSNCSA-N 0.000 description 6
- SCWYHUQOOFRVHP-MBLNEYKQSA-N Gly-Ile-Thr Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SCWYHUQOOFRVHP-MBLNEYKQSA-N 0.000 description 6
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 6
- VYUXYMRNGALHEA-DLOVCJGASA-N His-Leu-Ala Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O VYUXYMRNGALHEA-DLOVCJGASA-N 0.000 description 6
- AIPUZFXMXAHZKY-QWRGUYRKSA-N His-Leu-Gly Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O AIPUZFXMXAHZKY-QWRGUYRKSA-N 0.000 description 6
- MJUUWJJEUOBDGW-IHRRRGAJSA-N His-Leu-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CN=CN1 MJUUWJJEUOBDGW-IHRRRGAJSA-N 0.000 description 6
- UDLAWRKOVFDKFL-PEFMBERDSA-N Ile-Asp-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N UDLAWRKOVFDKFL-PEFMBERDSA-N 0.000 description 6
- CYHJCEKUMCNDFG-LAEOZQHASA-N Ile-Gln-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)NCC(=O)O)N CYHJCEKUMCNDFG-LAEOZQHASA-N 0.000 description 6
- ZUPJCJINYQISSN-XUXIUFHCSA-N Ile-Met-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)O)N ZUPJCJINYQISSN-XUXIUFHCSA-N 0.000 description 6
- YBKKLDBBPFIXBQ-MBLNEYKQSA-N Ile-Thr-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)O)N YBKKLDBBPFIXBQ-MBLNEYKQSA-N 0.000 description 6
- RMJWFINHACYKJI-SIUGBPQLSA-N Ile-Tyr-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N RMJWFINHACYKJI-SIUGBPQLSA-N 0.000 description 6
- BQSLGJHIAGOZCD-CIUDSAMLSA-N Leu-Ala-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O BQSLGJHIAGOZCD-CIUDSAMLSA-N 0.000 description 6
- PLDJDCJLRCYPJB-VOAKCMCISA-N Lys-Lys-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PLDJDCJLRCYPJB-VOAKCMCISA-N 0.000 description 6
- MNGBICITWAPGAS-BPUTZDHNSA-N Met-Ser-Trp Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O MNGBICITWAPGAS-BPUTZDHNSA-N 0.000 description 6
- IQJMEDDVOGMTKT-SRVKXCTJSA-N Met-Val-Val Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(O)=O IQJMEDDVOGMTKT-SRVKXCTJSA-N 0.000 description 6
- LQZZPNDMYNZPFT-KKUMJFAQSA-N Pro-Gln-Phe Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O LQZZPNDMYNZPFT-KKUMJFAQSA-N 0.000 description 6
- RDFQNDHEHVSONI-ZLUOBGJFSA-N Ser-Asn-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O RDFQNDHEHVSONI-ZLUOBGJFSA-N 0.000 description 6
- LSHUNRICNSEEAN-BPUTZDHNSA-N Ser-Val-Trp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CO)N LSHUNRICNSEEAN-BPUTZDHNSA-N 0.000 description 6
- QQWNRERCGGZOKG-WEDXCCLWSA-N Thr-Gly-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O QQWNRERCGGZOKG-WEDXCCLWSA-N 0.000 description 6
- MXDOAJQRJBMGMO-FJXKBIBVSA-N Thr-Pro-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O MXDOAJQRJBMGMO-FJXKBIBVSA-N 0.000 description 6
- KHUVIWRRFMPVHD-JYJNAYRXSA-N Tyr-Met-Val Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(O)=O KHUVIWRRFMPVHD-JYJNAYRXSA-N 0.000 description 6
- VLOYGOZDPGYWFO-LAEOZQHASA-N Val-Asp-Glu Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O VLOYGOZDPGYWFO-LAEOZQHASA-N 0.000 description 6
- KDKLLPMFFGYQJD-CYDGBPFRSA-N Val-Ile-Arg Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](C(C)C)N KDKLLPMFFGYQJD-CYDGBPFRSA-N 0.000 description 6
- CKTMJBPRVQWPHU-JSGCOSHPSA-N Val-Phe-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)O)N CKTMJBPRVQWPHU-JSGCOSHPSA-N 0.000 description 6
- 108010087924 alanylproline Proteins 0.000 description 6
- 230000000172 allergic effect Effects 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 108010043240 arginyl-leucyl-glycine Proteins 0.000 description 6
- 108010047857 aspartylglycine Proteins 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 239000013024 dilution buffer Substances 0.000 description 6
- 108010078144 glutaminyl-glycine Proteins 0.000 description 6
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 108010003700 lysyl aspartic acid Proteins 0.000 description 6
- 238000002703 mutagenesis Methods 0.000 description 6
- 231100000350 mutagenesis Toxicity 0.000 description 6
- 108010061238 threonyl-glycine Proteins 0.000 description 6
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 208000010668 atopic eczema Diseases 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 235000018185 Betula X alpestris Nutrition 0.000 description 4
- 235000018212 Betula X uliginosa Nutrition 0.000 description 4
- 244000241257 Cucumis melo Species 0.000 description 4
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 4
- SVSQSPICRKBMSZ-SRVKXCTJSA-N Lys-Pro-Gln Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O SVSQSPICRKBMSZ-SRVKXCTJSA-N 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 206010070834 Sensitisation Diseases 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 230000008313 sensitization Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 235000009847 Cucumis melo var cantalupensis Nutrition 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- GDOZQTNZPCUARW-YFKPBYRVSA-N Gly-Gly-Glu Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CCC(O)=O GDOZQTNZPCUARW-YFKPBYRVSA-N 0.000 description 3
- VEPBEGNDJYANCF-QWRGUYRKSA-N Gly-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCCN VEPBEGNDJYANCF-QWRGUYRKSA-N 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- 206010048908 Seasonal allergy Diseases 0.000 description 3
- ILZAUMFXKSIUEF-SRVKXCTJSA-N Ser-Ser-Phe Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ILZAUMFXKSIUEF-SRVKXCTJSA-N 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000013016 damping Methods 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 108010064235 lysylglycine Proteins 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 238000011533 pre-incubation Methods 0.000 description 3
- 238000002741 site-directed mutagenesis Methods 0.000 description 3
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 3
- 229960004906 thiomersal Drugs 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- PEEYDECOOVQKRZ-DLOVCJGASA-N Ala-Ser-Phe Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O PEEYDECOOVQKRZ-DLOVCJGASA-N 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000219427 Fagales Species 0.000 description 2
- 102000002151 Microfilament Proteins Human genes 0.000 description 2
- 108010040897 Microfilament Proteins Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 244000061176 Nicotiana tabacum Species 0.000 description 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229940096437 Protein S Drugs 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- LKJCABTUFGTPPY-HJGDQZAQSA-N Thr-Pro-Gln Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O LKJCABTUFGTPPY-HJGDQZAQSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000006287 biotinylation Effects 0.000 description 2
- 238000007413 biotinylation Methods 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000000586 desensitisation Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000003632 microfilament Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000219495 Betulaceae Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 241000726768 Carpinus Species 0.000 description 1
- 235000001543 Corylus americana Nutrition 0.000 description 1
- 240000007582 Corylus avellana Species 0.000 description 1
- 235000007466 Corylus avellana Nutrition 0.000 description 1
- 235000009842 Cucumis melo Nutrition 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- SQXZLVXQXWILKW-KKUMJFAQSA-N Lys-Ser-Phe Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O SQXZLVXQXWILKW-KKUMJFAQSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241000746983 Phleum pratense Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 201000004338 pollen allergy Diseases 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 108010026466 polyproline Proteins 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
- A61K39/36—Allergens from pollen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Beans For Foods Or Fodder (AREA)
Abstract
本发明提供垂枝桦植物花粉的Bet v 2主要变应原的低变应原性变体，及其预防或治疗变应性疾病的用途。
Description
本发明提供Bet v 2蛋白质的低变应原性序列变体、编码其的核酸分子、包含其的药物组合物以及它们在预防和治疗由来自垂枝桦(Betulaverrucosa)物种的植物花粉导致的变应性疾病中的用途。
背景技术
变态反应由免疫系统功能异常导致，所述免疫系统通过产生IgE-类抗体与花粉、螨、上皮和某些食物中含有的无害蛋白质反应。
最近的数据表明西方国家中超过10％的人口患有该疾病，其症状可随时间恶化，导致例如哮喘或对其他变应原致敏，由此造成选择适当的治疗方法更加困难。
与药理学疗法不同，特定的脱敏免疫疗法(SIT)是变应性疾病的唯一病原疗法，能够顺利地改变这类疾病的特征性免疫参数。
脱敏免疫疗法包括施用增加剂量的获自导致疾病的物质的标准提取物(疫苗)(1)。这样，患者对该物质的一类免疫耐受逐步降低，随后变应性症状消失。
但是，事实上引起严重副作用的风险(2)限制特定脱敏免疫疗法在治疗变应性疾病中的应用，虽然使用缓释疫苗或使用非注射途径施用的疫苗使该风险显著降低。
近年来大部分注意力已集中在开发有效、安全的疫苗上，尤其是包含诱变处理的重组蛋白(即能够有利地影响疾病的自然进程而不导致不希望的副作用的低变应原性变体)的疫苗(3)。
如果IgG抗体对于致敏变应原是特异性的，则SIT的有利因素之一是诱导。这类(保护)抗体能够抑制抗原-IgE结合，特别是抑制IgE与Bet v 2抗原结合，改变该分子的三维构像(4，5)。包含具有未改变免疫原性的低变应原性重组蛋白的疫苗的开发将改善变应性疾病的治疗。
分类学上称为山毛榉目(Fagales)的植物(桦树、桤木、榛树、橡树、角树)的花粉是温带地区导致变应性鼻炎和哮喘的最主要原因之一。桦树花粉的两种主要变应原，Bet v 1(以登录号X15877保存在GenBank的cDNA)和Bet v 2(登录号M65179)，是分子量分别为17和14kD的蛋白质(6，7)。Bet v2属于抑制蛋白家族，其是涉及调节真核细胞细胞骨架的遍在胞质蛋白质。它们与至少两种细胞(大)分子相互作用，该至少两种细胞(大)分子即磷脂酰肌醇-4，5-二磷酸，从而阻止C-γ磷脂酶(phospholypase)对该脂肪酸的水解(8)，和肌动蛋白，调控其的聚合作用(9)。抑制蛋白在成熟和萌发的花粉中的高表达暗示它们参与调节微丝前体，该微丝前体参与萌发过程(10)。抑制蛋白被认为是来自多种乔木和草本植物的花粉中的变应原，和多种水果和蔬菜中的变应原，因此抛开抑制蛋白仅在20％对花粉变应性的(过敏的)患者中发现的事实，它们被定义为“泛-变应原(pan-allergens)”(11，12)。
在大部分多种来源的植物抑制蛋白中的高序列同源性(高于60％)导致交叉致敏，不仅在来自相关植物(13)和不相关植物(14)的花粉之间，还在花粉和植物食品(aliment，15)之间，或在花粉和橡胶(latex)之间(16)。植物抑制蛋白和哺乳动物抑制蛋白之间的同源性较低，尽管证明了它们能够结合来自不同物种的肌动蛋白且显示出可交换性(17，18，19)。解释是所有的抑制蛋白具有相似的三维结构，如使用X-射线晶体学所示的(20，21，22)。
许多研究证实抑制蛋白的免疫等同物。事实上，已显示来自对确定的花粉致敏的患者的IgE能够结合不同来源的抑制蛋白，结合抑制蛋白的IgE可以相互抑制(16)。
不同花粉之间的高交叉反应性使得单独的抑制蛋白可用于变应反应诊断，重组Bet v 2通常用作选择抑制蛋白特异性IgE测定的变应原(23，24)。
存在多种测定抑制蛋白IgE表位的研究。
根据同时期相同小组进行的下述研究(26)，Vrtala(1996)在Phe44和Gln47诱变Bet v 2，将它们变成Tyr44、Glu47和Asn47，所述研究中鉴定了单克隆抗体4A6识别的线性表位。使用合成的十二肽(跨越Bet v2的整个氨基酸序列)对该抗体识别的表位作图。更有效结合该抗体的多肽含有氨基酸38-49和40-51之间的区域。IgG-肽结合中Gln47残基的重要性由下述证据证明：4A6不能够识别来自烟草(Nicotiana tabacum)和梯牧草(Phleum pratense)的抑制蛋白，其序列显示谷氨酸位于Bet v 2的Gln47。与Gln47→Glu47突变不同，从Phe44到Tyr44的改变或从GIn47到Asn47的改变不影响抗体的结合。如免疫印记和ELISA试验(25)所示，对重组Bet v 2应用相同的诱变(Gln47到Glu，或Asn和Phe44到Tyr44)不能够降低抑制蛋白和IgE之间的结合。
在1997年公开的随后的研究(22)中，通过克隆桦树抑制蛋白cDNA的随机片段鉴定了主要的IgE表位，该cDNA来自用对抑制蛋白变应性的患者血清分析的表达文库。证明三个区域更有反应性，即对应于位于氨基端的α螺旋(aa 1-30)的区域。羧基端的α螺旋(aa 106-132)的区域，以及包含残基30-50的片段的区域。
在随后的研究(23)中，对IgE表位的研究基于来自不同植物的抑制蛋白的理论结构模型与桦树或橡胶抑制蛋白晶体之间的比较。预测了11个可能的构象表位(包含相邻的氨基酸区域)，其中至少20％是暴露于表面的。氨基酸序列和构象模型的比较得到两类表位：物种特异性表位(由高变异性表征)和高度保守表位，后者更可能涉及不同植物抑制蛋白之间的交叉反应。氨基酸序列比对反映Fedorov研究(22)的结果，证明在抑制蛋白N-端具有两个可能的线性表位，在残基30-80之间有三个可能的线性表位，且其余两个在抑制蛋白C-端。所有这些区域在该研究中所评测的植物抑制蛋白中均是高度保守的。可能的构象表位的预测基于橡胶抑制蛋白Hev b8的3D模型的分析。该分析证明了选自表位中心的12个突出的残基。虽然所有可能的表位均是构想性的，它们包含线性序列以及保守或可变的残基。在该研究中没有报导证实所研究的表位的特异性IgE-结合能力的测试。
更为近期的出版物涉及甜瓜(Cucumis melo)抑制蛋白IgE表位的鉴定(27)。通过测定跨越该蛋白质的整个氨基酸序列的肽的IgE反应性，鉴定了两个线性表位，其中E1被对甜瓜变应性的患者血清强烈识别，包含残基66-75和81-93，E2由氨基酸95-99和122-131组成。另外两个表位被较弱的IgE应答表征，即E3(残基2-10)和E4(35-45)。对应甜瓜抑制蛋白3D模型的表位E1和E2的肽的重叠表示具有良好定义的静电性质的两个区域：E1和E2，其分别和正电性和负电性蛋白质结构域相关。
来自文献的数据表示IgE抑制蛋白表位位于其中的分子部分，但是未指出涉及IgE结合的氨基酸。
发明内容
现已发现通过取代或缺失Bet v 2变应原序列中的一个或多个氨基酸残基使得该变应原对IgE抗体的反应性降低。
第一方面，本发明提供低变应原性蛋白质，其是Bet v 2变应原的序列变体，且其特征在于：
1)与野生型Bet v 2变应原(SEQ ID NO：1)相比，对IgE的反应性降低；
2)氨基酸序列为：
a)与SEQ ID NO：1至少90％相同，优选至少93％相同，进一步优先至少97％相同；
b)与SEQ ID NO：1的序列比对表明SEQ ID NO：1在对应于(matching)Ser39、Lys 45、Lys88或Lys89的Ser或Lys残基处具有至少一个取代或缺失。
在优选的实施方案中，本发明的Bet v 2变应原的变体在所示位置具有1-3个中的多个取代或缺失，其中产生单、双或三取代和/或缺失变体。虽然可以在Bet v 2分子中同时存在不同氨基酸残基的取代和缺失，优选在指示位点通过一个或多个残基的单取代获得变体，特别是此类残基被中性、极性或酸性氨基酸置换的变体，所述中性、极性或酸性氨基酸选自Ala、Thr、Gly、Pro、Leu、Ile、Ser、Phe、Glu、Asp，更优选选自Ala、Thr、Ser、Gly、Glu、Asp。
本发明变体的实例示于SEQ ID NO：2(1个残基取代)、SEQ ID NO：3(1个残基取代)、SEQ ID NO：4(2个残基取代)、SEQ ID NO：5(3个残基取代)和SEQ ID NO：6(3个残基取代)。
相对于野生型对应物(counterpart)，本发明的Bet v 2变应原取代和/或缺失变体表现出与垂枝桦花粉-变应性患者血清的IgE的反应性，其降低至少10％，优选至少50％，更优选至少90％，其中IgE反应性通过例如ELISA测定的方法检测。
来自变应性患者血清库的蛋白质SEQ ID NO：2-6的IgE反应性由ELISA测定检测(图1)。相对于野生型Bet v 2变应原(SEQ ID NO：1)，当(SEQID NO：2)、(SEQ ID NO：3)、(SEQ ID NO：4)和(SEQ ID NO：5和6)蛋白质与来自桦树花粉变应性患者的血清库孵育时，观察到IgE反应性平均降低92％(SEQ IDNO：2)、13％(SEQ ID NO：3)、97％(SEQ ID NO：4)和93％(SEQ ID NO：5和6)。
这些结果由REAST抑制试验证实，该试验可以评测来自不同蛋白质的同源表位的反应性。在存在1.45ng抑制物时，当血清用相同的蛋白质预处理过，野生型Bet v 2(SEQ ID NO：1)与来自变应性患者血清库的IgE的结合82.6％抑制，当血清用变体SEQ ID NO：2和SEQ ID NO：3预温育时，分别是40.4％和71％抑制，而当血清分别用相同量的双取代变体(SEQ IDNO：4)和三取代变体(SEQ ID NO：5和SEQ ID NO：6)预温育时，观察到的抑制仅为13.4％、4％和8.8％(图2)。
这些结果明确表明SEQ ID NO：1第39、45、88、89位的氨基酸参与IgE对Bet v 2变应原的识别。
另外，Balb/c小鼠免疫接种试验证明野生型Bet v 2变应原和低变应原性蛋白质SEQ ID NO：5(选自作为示例性突变变应原)均能诱导IgG-特异性免疫应答(图3)。抗SEQ ID NO：5抗体能够识别野生型-对应物SEQ IDNO：1(图4)，证明第45、88、89位Lys-残基的取代并不导致分子免疫原性的重大改变，且改变其IgG表位。相反，不相关抗原免疫的小鼠血清中存在的抗体不能够识别野生型Bet v 2和SEQ ID NO：5。
另一方面，本发明提供Bet v 2片段相应的免疫活性肽，所述免疫活性肽包含至少一种上述取代和/或缺失。所述肽优选含有15-35个氨基酸残基、更优选15-20个氨基酸残基。本文所用术语“免疫活性肽”意指能够引发不依赖IgE的免疫应答的肽。
使用本领域技术人员已知的方法和技术，通过诱变野生型Bet v 2cDNA序列(SEQ ID NO：7)可容易地制备本发明的取代和/或缺失变体。
编码SEQ ID NO：2-6所示的单、双和三取代变体的cDNA序列报告于SEQ ID NO：8-12。
另一方面，本发明提供编码本文公开的低变应原性Bet v 2变体的核酸分子、衍生自其的肽、包含该分子的表达载体，其中所述分子与真核细胞或原核细胞中控制其表达的遗传元件(例如转录启动子、增强子、信号及前导序列，或转录调控中涉及的其他序列)功能性连接。载体的例子包括质粒、病毒和噬菌体，然而遗传工程中通常使用的任何其他载体也可以使用。
本发明还包含用本发明载体转化或转染的原核或真核宿主细胞。原核细胞例如大肠杆菌(Escherichia coli)或枯草杆菌(Bacillus subtilis)，或真核细胞例如酿酒酵母(Saccharomyces cerevisiae)通常用作克隆或cDNA表达载体。
另外，本发明的低变应原性变体可作为融合蛋白制备。
由于它们降低的IgE反应性，本发明的Bet v 2变体可方便地用于制备药物组合物(例如片剂)，所述药物组合物用于预防或治疗垂枝桦花粉的变应性个体。
因此本发明的另一方面在于药物组合物，其包含有效量的本文提供的低变应原性Bet v 2变体，该变体任选和垂枝桦的其他变应原，和/或药学可接受载体和赋形剂组合。在优选实施方案中，药物组合物以疫苗形式用于预防或治疗包括支气管哮喘、变应性鼻炎、变应性皮炎和变应性结膜炎的变应性疾病。免疫接种的理论和操作是本领域技术人员已知的(28，29)。
下列实施例进一步阐明本发明。除非另行指出，实施例中所用方法描述于Sambrook，Fritsch ET Maniatis“Molecular cloning.A laboratorymanual”第二版，第1-2-3卷，CSH Lab出版，1989。
附图简述
图1：ELISA分析IgE与Bet v 2变应原和Bet v 2低变应原性变体的反应性；
图2：IgE与Betv 2变应原结合的抑制；
图3：突变IgE与各免疫原性蛋白质的应答；
图4：SEQ ID NO：5免疫的小鼠中的IgG应答。
实施例1-Bet v 2变应原编码cDNA的位点特异性诱变
Bet v 2变应原编码cDNA(SEQ ID NO：7)的位点特异性诱变通过原核载体(pBluescript，GenBank登录号X52327)中的cDNA克隆，然后是PCR扩增进行。PCR反应中用作引物的寡核苷酸(表)具有合适的碱基取代。对于每个诱变，使用结合到DNA链相应区域的互补寡核苷酸(30)。扩增后，限制酶DpnI催化的酶促消化选择性降解未改变的原模板。然后用诱变的分子转化大肠杆菌细胞。根据桑格(法)对获自单细菌菌落的克隆进行测序，以确定cDNA中正确的碱基修饰以及不存在非特异性突变。
表.位点特异性诱变中用作引物的寡核苷酸序列。
突变的碱基为黑体。
| 寡核苷酸 | 序列 |
| Bet v2 S39 | ggg ccc aga gcg ctt cct tcc cac ag |
| Bet v2 K45 | cct tcc cac agt tta cgc ctc agg aaa tc |
| Bet v2 K88-89 | gtc atc cgt gga ggg gag gga tct gga g |
实施例2-制备Bet v 2蛋白及其变体
根据标准方案(31，32)在大肠杆菌中克隆并表达野生型(SEQ ID NO.7)和诱变的(SEQ ID NO：8-12)Bet v 2cDNA。细胞离心收集，重悬于PBS1X(6.46mM NaH2PO4、1.47mM KH2PO4、136.89mM NaCl)中并超声裂解。离心分离重组蛋白。含有不溶蛋白质聚集体的沉淀重悬于PBS 1X、6M尿素(变性缓冲液)中并在4℃下搅拌60分钟。溶解的重组蛋白从不溶的残渣中离心分离，用PBS 1X透析，滤过1μM的滤器并通过使用用聚-脯氨酸衍生化的琼脂糖柱(Sigma，Milan，意大利)亲和层析纯化。用PBS 1X、2M尿素洗涤后，用PBS 1X、8M尿素洗脱重组蛋白质，并在PBS 1X溶液中4℃透析16小时来重折叠。
实施例3-变应性受试者血清的表征
血清收集自具有对垂枝桦花粉有季节性变态反应临床既往症，并具有对Bet v 2变应原有RAST 3+和4+特异反应性的个体，然后集中这些血清并以这种形式使用。来自非变应性患者的血清库用作阴性对照。
实施例4-Bet v 2变体对血清库中IgE的反应性的ELISA分析
50mM碳酸盐/碳酸氢盐缓冲液(pH 9.6)中相同量的野生型变应原和突变变体(1μg)在4℃下温育16小时以吸附到ELISA分析用聚苯乙烯(polystirene)板的孔上。该孔用洗涤溶液(60mM含有0.05％Tween-20的磷酸盐缓冲液，pH 6.5)洗涤，并用稀释溶液(150mM磷酸盐缓冲液中的25％山羊血清、1mM EDTA、0.05％Tween 20、0.01％乙基汞硫代水杨酸钠，pH 7.4)封闭。70μl人血清RAST 3+和4+库(在稀释缓冲液中)的整分试样加入至每个样品，并于25℃温育2小时。洗涤三次后，加入过氧化物酶缀合的抗人-IgE血清(稀释缓冲液中1∶1500)，接着25℃温育1.5小时。洗涤三次后加入100μl TMB试剂(BioFX Laboratories，Owings Mills，MD)并在25℃温育15分钟进行比色反应。加入100μl 1N HCl终止反应并使用酶标仪(microplate reader spectrophotometer)在450nm处读数。
实施例5-REAST抑制测定。Bet v 2变体抑制生物素化Bet v 2与血清库中包含的IgE的结合
1∶3稀释于稀释缓冲液(150mM磷酸盐缓冲液中的25％山羊血清、1mM EDTA、0.05％Tween 20、0.01％乙基汞硫代水杨酸钠，pH 7.4)中的对Bet v 2的人血清库RAST 4+和3+的整分试样(50μl)与野生型变应原及其突变体的连续稀释物(从67ng/ml开始)在25℃下预温育1.5小时。然后将混合物加入ELISA聚苯乙烯(polystirene)平板的小孔中并在25℃温育1.5小时，该小孔吸附人抗-IgE。用0.06M的磷酸缓冲液、0.05％Tween-20，pH6.5洗涤三次后，加入稀释缓冲液中的0.1ml生物素化Bet v 2抗原(85.3ng/ml)并在25℃温育1小时。洗涤三次后，25℃下加入过氧化物酶-链霉亲和素(0.1μg/ml)30分钟。用100μl 1N HCl进行比色反应并使用分光光度仪在450nm处读数。
抑制百分数计算如下：100x[(A-B)/A]，其中A是无抑制物时450nm处测量的吸光度，而B是存在抑制物时的吸光度。
实施例6-免疫接种Balb/c小鼠的方案
5只雌性Balb/c小鼠(Charles River)的两个组用200μl的乳剂皮下免疫，该乳剂含有100μl完全弗氏佐剂和100μl盐水中的20μg抗原(SEQ IDNO：1，SEQ ID NO：5)。另外三次加强免疫以1周的间隔进行，用不完全佐剂替换完全佐剂。作为对照，5只小鼠施用不相关的抗原。末次免疫后7天，从颈静脉获取血样，用于ELISA以检验抗体与每种免疫原性物质的应答。对于SEQ ID NO：5免疫的小鼠，还分析了识别野生型蛋白质的能力。
实施例7-ELISA分析免疫小鼠中的IgG-特异性应答
50mM碳酸盐/碳酸氢盐缓冲液(pH 9.6)中相同量的野生型Bet v 2和变体SEQ ID NO：5(0.25μg)在4℃下温育16小时以吸附到ELISA分析用聚苯乙烯板的孔上。该孔用洗涤溶液(60mM含有0.05％Tween-20的磷酸盐缓冲液，pH 6.5)洗涤，并用稀释溶液(150mM磷酸盐缓冲液中的25％马血清、1mM EDTA、0.05％Tween 20、0.01％乙基汞硫代水杨酸钠，pH 7.4)封闭。100μl每只小鼠血清的连续稀释物(在稀释缓冲液中)的整分试样置于每孔中，并于25℃温育2小时。
洗涤三次后，在稀释缓冲液中1∶2000稀释过氧化物酶缀合的抗小鼠IgG血清，并加入到小孔中，接着25℃温育1.5小时。洗涤三次后加入100μlTMB试剂(BioFX Laboratories，Owings Mills，MD)并在25℃温育15分钟进行比色反应。用100μl 1N HCl终止反应并使用分光光度仪在450nm处读数。图3和4显示通过分析每组的5只小鼠的血清获得的平均反应性。
参考文献
1)Malling H.J.，(1998)“Immunotherapy as an effective tool in allergytreatment”.Allergy，53：461.
2)Toubi E.，Kessel A.，Blant A.，Golan T.D.，(1999)“Follow-up aftersystemic adverse reactions of immunotherapy”.Allergy，54(6)：617-620.
3)Akdis C.A.，Blaser K.，(2000)“Regulation of specific immune responseby chemical and structural modifications of allergens”.Int.Arch.AllergyImmmunol.，121(4)：261-269.
4)Visco V，Dolecek C，Denépoux S，Le Mao J，Guret C，Rousset F，Guinnepain MT，Kraft D，Valenta R，Weyer A，Banchereau J，Lebecque S.(1996).“Human IgG monoclonal antibodies that modulate the binding ofspecific IgE to birch pollen Bet v 1”.J.Immunol.157：956-962.
5)Vrtala S，Ball T，Spitzauer s，Pandjaitan B，Suphioglu C，Knox B，SperrWR，Valent P，Kraft D，Valenta R.(1998).“Immunization with purified naturaland recombinant allergens induces mouse IgG1 antibodies that recognizesimilar epitopes as human IgE and inhibit the human IgE-allergen interactionand allergen-induced basophil degranulation”.J Immunol 160：6137.
6)Breiteneder H.，Pettanburger K.，Bito A et al.(1989).“The gene codingfor the major birch pollen allergen Bet v 1，is highly homologous to a peadisease resistance response gene”.EMBO J，8：1935-1938.
7)Valenta R.，Duchene M.，Pettenburger K.，Sillaber C.，Valent P.，Bettelheim P.，Breitenbach M.，Rumpold H.，Kraft D.，Scheiner O.(1991).″Identification of profilin as a novel pollen allergen；IgE autoreactivity insensitized individuals.″.Science 253：557-560
8)Goldschmidt-Clermont PJ.，Kim J.，Machesky LM.，Rhee S.，PollardTD.(1991).“Regulation of phospholipase C-Y by profilin and tytosinephosphorilation”.Science，251：1231-3.
9)Carlsson I.，Nystrom LE.，Sundkvist F.，Markey F.，Lindberg U.(1977).“Actin polymerization is influenced by profilin，a low molecular weight proteinin non muscle-cells”.J Mol Biol，115：465：83.
10)Mittermann I，Swoboda I，Pierson E，Eller N，Kraft D，Valenta R，Heberle-Bors E.(1995).“Molecular cloning and characterization of profilinfrom tobacco (Nicotiana tabacum)：increased profilin expression duringpollen maturation”.Plant Mol Biol.27(1)：137-46.
11)Valenta R.，Duchene M.，Ebner C.，Valent P.，Sillaber C.，Deviller P.，Ferreira F.，Tejkl M.，Edelmann H.，Kraft D.，et al.(1992).“Profilins constitutea novel family of functional plant pan-allergens”J.Exp.Med，175：377-85.
12)Radauer C.，Hoffmann-Sommergruber K.(2004).“Profilin”.Plant foodallergens.IN mills ENC，sherry PR，Editors.Plant food allergen.Oxford：Blackwell Pubishing.(2004).105-24.
13)Niederberger V，Pauli G，Gronlund H，Froschl R，Rumpold H，Kraft D，Valenta R，Spitzauer S.(1998).“Recombinantbirch pollen allergens(rBet v 1and rBet v 2)contain most of the IgE epitopes present in birch，alder，hornbeam，hazel，and oak pollen：A quantitative IgE inhibition study with serafrom different populations”.J.Allergy Clin Immunol.102：579-91.
14)Mari A.，(2001).“Multiple pollen sensitization：a molecular approach tothe diagnosis”.Int Arch Allergy Immunol.125：(57-65).
15)van Ree R.，Voitenko V.，van Leeuwen WA.，Aalberse RC.(1992).“Profilin is a cross-reactive allergen in pollen and vegetabe foods”.Int ArchAllergy Immunol 98：97：104.
16)Ganglberger E.，Radauer C.，Wagner S et al.(2001).“Hev b 8，theHevea brasiliensis latex profilin，is a cross-reactive allergen of latex，plantfoods and pollen”.Int Arch Allergy Immunol.125：216-27.
17)Giehl K，Valenta R，Rothkegel M，Ronsiek M，Mannherz HG，JockuschBM.(1994)“Interaction of plant profilin with mammalian actin”.Eur JBiochem.226(2)：681-9.
18)Staiger CJ，Yuan M，Valenta R，Shaw PJ，Warn RM，Lloyd CW(1994).“Microinjected profilin affects cytoplasmic streaming in plant cells by rapidlydepolymerizing actin microfilaments”.Curr Biol.Mar 1；4(3)：215-9.
19)Rothkegel M，Mayboroda O，Rohde M，Wucherpfennig C，Valenta R，Jockusch BM.(1g96).“Plant and animal profilins are functionally equivalentand stabilize microfilaments in living animal cells”.J Cell Sci.109(Pt 1)：83-90.
20)Almo SC，Pollard TD，Way M，Lattman EE(1994).“Purification，characterization and crystallization of Acanthamoeba profilin expressed inEscherichia coli”.J Mol Biol.236(3)：950-2.
21)Fedorov AA，Pollard TD，Almo SC.(1994).“Purification，characterization and crystallization of human platelet profilin expressed inEscherichia coli”.J Mol Biol.241(3)：480-2.
22)Fedorov AA，Ball T，Mahoney NM，Valenta R，Almo SC.(1997).“Themolecular basis for allergen cross-reactivity：crystal structure and IgE-epitopemapping of birch pollen profilin”.Structure.5：33-45
23)Radauer C，Willerroider M，Fuchs H，Hoffmann-Sommergruber K，Thalhamer J，Ferreira F，Scheiner O，Breiteneder H.(2006).“Cross-reactiveand species-specific immunoglobulin E epitopes of plant profilins：anexperimental and structure-based analysis”.Journal Clin Exp Allergy 2006；36(7)：920-929.
24)Rossi RE.，Monasterolo G.，Operti D.，Corsi M.(1996).“Evaluation ofrecombinant allergens Bet v 1 and Bet v 2(profilin)by Pharmacia CAPsystem in patients with pollen-related allergy to birch and apple”.Allergy，51：940-5.
25)Vrtala S，Wiedemann P，Mittermann I，Eichler HG，Sperr WR，ValentP，Kraft D，Valenta F.(1996).“High-level expression in Escherichia coli andpurification of recombinant plant profilins：comparison of IgE-binding capacityand allergenic activity”.Biochem Biophys Res Commun 226(1)：42-50.
26)Wiedemann P，Giehl K，Almo SC，Fedorov AA，Girvin M，SteinbergerP，Rudiger M，Ortner M，Sippl M，Dolecek C，Kraft D，Jockusch B，Valenta R.(1996).“Molecular and structural analysis of a continuous birch profilinepitope defined by a monoclonal antibody”.J Biol Chem.271(47)：29915-29921.
27)Lopez-Torrejon G，Diaz-Perales A，Rodriguez J，Sanchez-Monge R，Crespo JF，Salcedo G，Pacios LF.(2007).“An experimental andmodeling-based approach to locate IgE epitopes of plant profilin allergens”.JAllergy Clin Immunol.119：1481-8.
28)Paul，(1989)，“Fundamental Immunology”，Raven press，New York.
29)Cryz，S.J.(1991)，“Immunotherapy and Vaccines”，VCHVerlagsgesellschaft.
30)Wang W.，Malcolm BA.(2002).“Two-stage polymerase chain reactionprotocol allowing introduction of multiple mutations，deletions，and insertions，using QuikChange site-directed mutagenesis”.Methods Mol Biol.；182：37-43.
31)Younghee Kim.(2004).“Cloning and Expression of a Lipase Genefrom Rice(Oryza sativa cv.Dongjin)”.Mol.Cells，18(1)：40-45.
32)Asturias JA，lbarrola I，Eseverri JL，Arilla MC，Gonzales-Rioja R，Martinez A.(2004).“PCR-based cloning and immunological characterizationof Parietaria judaica pollen profilin”.J Investig Allergol Clin Immunol，14：43-48.
序列表
<110>洛法玛有限公司(LOFARMA S.P.A.)
<120>垂枝桦花粉主要变应原的低变应原性变体
<130>8025MEUR
<160>12
<170>PatentIn版本3.3
<210>1
<211>133
<212>PRT
<213>未知
<220>
<223>来自垂枝桦(Betula verrucosa)的野生型Bet v 2
<400>1
Met Ser Trp Gln Thr Tyr Val Asp Glu His Leu Met Cys Asp Ile Asp
1 5 10 15
Gly Gln Ala Ser Asn Ser Leu Ala Ser Ala Ile Val Gly His Asp Gly
20 25 30
Ser Val Trp Ala Gln Ser Ser Ser Phe Pro Gln Phe Lys Pro Gln Glu
35 40 45
Ile Thr Gly Ile Met Lys Asp Phe Glu Glu Pro Gly His Leu Ala Pro
50 55 60
Thr Gly Leu His Leu Gly Gly Ile Lys Tyr Met Val Ile Gln Gly Glu
65 70 75 80
Ala Gly Ala Val Ile Arg Gly Lys Lys Gly Ser Gly Gly Ile Thr Ile
85 90 95
Lys Lys Thr Gly Gln Ala Leu Val Phe Gly Ile Tyr Glu Glu Pro Val
100 105 110
Thr Pro Gly Gln Cys Asn Met Val Val Glu Arg Leu Gly Asp Tyr Leu
115 120 125
Ile Asp Gln Gly Leu
130
<210>2
<211>133
<212>PRT
<213>未知
<220>
<223>Bet v 2突变体
<400>2
Met Ser Trp Gln Thr Tyr Val Asp Glu His Leu Met Cys Asp Ile Asp
1 5 10 15
Gly Gln Ala Ser Asn Ser Leu Ala Ser Ala Ile Val Gly His Asp Gly
20 25 30
Ser Val Trp Ala Gln Ser Ala Ser Phe Pro Gln Phe Lys Pro Gln Glu
35 40 45
Ile Thr Gly Ile Met Lys Asp Phe Glu Glu Pro Gly His Leu Ala Pro
50 55 60
Thr Gly Leu His Leu Gly Gly Ile Lys Tyr Met Val Ile Gln Gly Glu
65 70 75 80
Ala Gly Ala Val Ile Arg Gly Lys Lys Gly Ser Gly Gly Ile Thr Ile
85 90 95
Lys Lys Thr Gly Gln Ala Leu Val Phe Gly Ile Tyr Glu Glu Pro Val
100 105 110
Thr Pro Gly Gln Cys Asn Met Val Val Glu Arg Leu Gly Asp Tyr Leu
115 120 125
Ile Asp Gln Gly Leu
130
<210>3
<211>133
<212>PRT
<213>未知
<220>
<223>Bet v 2突变体
<400>3
Met Ser Trp Gln Thr Tyr Val Asp Glu His Leu Met Cys Asp Ile Asp
1 5 10 15
Gly Gln Ala Ser Asn Ser Leu Ala Ser Ala Ile Val Gly His Asp Gly
20 25 30
Ser Val Trp Ala Gln Ser Ser Ser Phe Pro Gln Phe Thr Pro Gln Glu
35 40 45
Ile Thr Gly Ile Met Lys Asp Phe Glu Glu Pro Gly His Leu Ala Pro
50 55 60
Thr Gly Leu His Leu Gly Gly Ile Lys Tyr Met Val Ile Gln Gly Glu
65 70 75 80
Ala Gly Ala Val Ile Arg Gly Lys Lys Gly Ser Gly Gly Ile Thr Ile
85 90 95
Lys Lys Thr Gly Gln Ala Leu Val Phe Gly Ile Tyr Glu Glu Pro Val
100 105 110
Thr Pro Gly Gln Cys Asn Met Val Val Glu Arg Leu Gly Asp Tyr Leu
115 120 125
Ile Asp Gln Gly Leu
130
<210>4
<211>133
<212>PRT
<213>未知
<220>
<223>Bet v 2突变体
<400>4
Met Ser Trp Gln Thr Tyr Val Asp Glu His Leu Met Cys Asp Ile Asp
1 5 10 15
Gly Gln Ala Ser Asn Ser Leu Ala Ser Ala Ile Val Gly His Asp Gly
20 25 30
Ser Val Trp Ala Gln Ser Ser Ser Phe Pro Gln Phe Lys Pro Gln Glu
35 40 45
Ile Thr Gly Ile Met Lys Asp Phe Glu Glu Pro Gly His Leu Ala Pro
50 55 60
Thr Gly Leu His Leu Gly Gly Ile Lys Tyr Met Val Ile Gln Gly Glu
65 70 75 80
Ala Gly Ala Val Ile Arg Gly Gly Glu Gly Ser Gly Gly Ile Thr Ile
85 90 95
Lys Lys Thr Gly Gln Ala Leu Val Phe Gly Ile Tyr Glu Glu Pro Val
100 105 110
Thr Pro Gly Gln Cys Asn Met Val Val Glu Arg Leu Gly Asp Tyr Leu
115 120 125
Ile Asp Gln Gly Leu
130
<210>5
<211>133
<212>PRT
<213>未知
<220>
<223>Bet v 2突变体
<400>5
Met Ser Trp Gln Thr Tyr Val Asp Glu His Leu Met Cys Asp Ile Asp
1 5 10 15
Gly Gln Ala Ser Asn Ser Leu Ala Ser Ala Ile Val Gly His Asp Gly
20 25 30
Ser Val Trp Ala Gln Ser Lys Ser Phe Pro Gln Phe Thr Pro Gln Glu
35 40 45
Ile Thr Gly Ile Met Lys Asp Phe Glu Glu Pro Gly His Leu Ala Pro
50 55 60
Thr Gly Leu His Leu Gly Gly Ile Lys Tyr Met Val Ile Gln Gly Glu
65 70 75 80
Ala Gly Ala Val Ile Arg Gly Gly Glu Gly Ser Gly Gly Ile Thr Ile
85 90 95
Lys Lys Thr Gly Gln Ala Leu Val Phe Gly Ile Tyr Glu Glu Pro Val
100 105 110
Thr Pro Gly Gln Cys Asn Met Val Val Glu Arg Leu Gly Asp Tyr Leu
115 120 125
Ile Asp Gln Gly Leu
130
<210>6
<211>133
<212>PRT
<213>未知
<220>
<223>Bet v 2突变体
<400>6
Met Ser Trp Gln Thr Tyr Val Asp Glu His Leu Met Cys Asp Ile Asp
1 5 10 15
Gly Gln Ala Ser Asn Ser Leu Ala Ser Ala Ile Val Gly His Asp Gly
20 25 30
Ser Val Trp Ala Gln Ser Ala Ser Phe Pro Gln Phe Lys Pro Gln Glu
35 40 45
Ile Thr Gly Ile Met Lys Asp Phe Glu Glu Pro Gly His Leu Ala Pro
50 55 60
Thr Gly Leu His Leu Gly Gly Ile Lys Tyr Met Val Ile Gln Gly Glu
65 70 75 80
Ala Gly Ala Val Ile Arg Gly Gly Glu Gly Ser Gly Gly Ile Thr Ile
85 90 95
Lys Lys Thr Gly Gln Ala Leu Val Phe Gly Ile Tyr Glu Glu Pro Val
100 105 110
Thr Pro Gly Gln Cys Asn Met Val Val Glu Arg Leu Gly Asp Tyr Leu
115 120 125
Ile Asp Gln Gly Leu
130
<210>7
<211>402
<212>DNA
<213>未知
<220>
<223>来自垂枝桦的野生型Bet v 2的编码序列
<400>7
atgtcgtggc aaacgtacgt ggatgaacat ttgatgtgcg atatcgacgg gcaagccagc 60
aactcgctgg catctgcgat cgtcggtcac gatggctctg tgtgggccca gagctcttcc 120
ttcccacagt ttaagcctca ggaaatcact ggtatcatga aggactttga ggagccgggt 180
catcttgctc cgacgggctt acaccttggg ggcataaaat acatggtcat ccagggagag 240
gctggtgctg tcatccgtgg aaagaaggga tctggaggta ttactataaa gaagactggt 300
caagctctcg tttttggcat ctatgaagag cctgtgacac caggacagtg caacatggtt 360
gttgagaggt tgggggatta ccttattgac cagggcctgt ag 402
<210>8
<211>402
<212>DNA
<213>未知
<220>
<223>Bet v 2突变体的编码序列
<400>8
atgtcgtggc aaacgtacgt ggatgaacat ttgatgtgcg atatcgacgg gcaagccagc 60
aactcgctgg catctgcgat cgtcggtcac gatggctctg tgtgggccca gagcgcttcc 120
ttcccacagt ttaagcctca ggaaatcact ggtatcatga aggactttga ggagccgggt 180
catcttgctc cgacgggctt acaccttggg ggcataaaat acatggtcat ccagggagag 240
gctggtgctg tcatccgtgg aaagaaggga tctggaggta ttactataaa gaagactggt 300
caagctctcg tttttggcat ctatgaagag cctgtgacac caggacagtg caacatggtt 360
gttgagaggt tgggggatta ccttattgac cagggcctgt ag 402
<210>9
<211>402
<212>DNA
<213>未知
<220>
<223>Bet v 2突变体的编码序列
<400>9
atgtcgtggc aaacgtacgt ggatgaacat ttgatgtgcg atatcgacgg gcaagccagc 60
aactcgctgg catctgcgat cgtcggtcac gatggctctg tgtgggccca gagctcttcc 120
ttcccacagt ttacgcctca ggaaatcact ggtatcatga aggactttga ggagccgggt 180
catcttgctc cgacgggctt acaccttggg ggcataaaat acatggtcat ccagggagag 240
gctggtgctg tcatccgtgg aaagaaggga tctggaggta ttactataaa gaagactggt 300
caagctctcg tttttggcat ctatgaagag cctgtgacac caggacagtg caacatggtt 360
gttgagaggt tgggggatta ccttattgac cagggcctgt ag 402
<210>10
<211>402
<212>DNA
<213>未知
<220>
<223>Bet v 2突变体的编码序列
<400>10
atgtcgtggc aaacgtacgt ggatgaacat ttgatgtgcg atatcgacgg gcaagccagc 60
aactcgctgg catctgcgat cgtcggtcac gatggctctg tgtgggccca gagctcttcc 120
ttcccacagt ttaagcctca ggaaatcact ggtatcatga aggactttga ggagccgggt 180
catcttgctc cgacgggctt acaccttggg ggcataaaat acatggtcat ccagggagag 240
gctggtgctg tcatccgtgg aggggaggga tctggaggta ttactataaa gaagactggt 300
caagctctcg tttttggcat ctatgaagag cctgtgacac caggacagtg caacatggtt 360
gttgagaggt tgggggatta ccttattgac cagggcctgt ag 402
<210>11
<211>402
<212>DNA
<213>未知
<220>
<223>Bet v 2突变体的编码序列
<400>11
atgtcgtggc aaacgtacgt ggatgaacat ttgatgtgcg atatcgacgg gcaagccagc 60
aactcgctgg catctgcgat cgtcggtcac gatggctctg tgtgggccca gagctcttcc 120
ttcccacagt ttacgcctca ggaaatcact ggtatcatga aggactttga ggagccgggt 180
catcttgctc cgacgggctt acaccttggg ggcataaaat acatggtcat ccagggagag 240
gctggtgctg tcatccgtgg aggggaggga tctggaggta ttactataaa gaagactggt 300
caagctctcg tttttggcat ctatgaagag cctgtgacac caggacagtg caacatggtt 360
gttgagaggt tgggggatta ccttattgac cagggcctgt ag 402
<210>12
<211>402
<212>DNA
<213>未知
<220>
<223>Bet v 2突变体的编码序列
<400>12
atgtcgtggc aaacgtacgt ggatgaacat ttgatgtgcg atatcgacgg gcaagccagc 60
aactcgctgg catctgcgat cgtcggtcac gatggctctg tgtgggccca gagcgcttcc 120
ttcccacagt ttaagcctca ggaaatcact ggtatcatga aggactttga ggagccgggt 180
catcttgctc cgacgggctt acaccttggg ggcataaaat acatggtcat ccagggagag 240
gctggtgctg tcatccgtgg aggggaggga tctggaggta ttactataaa gaagactggt 300
caagctctcg tttttggcat ctatgaagag cctgtgacac caggacagtg caacatggtt 360
gttgagaggt tgggggatta ccttattgac cagggcctgt ag 402
Claims (11)
1.低变应原性蛋白质，其是Bet v2主要变应原的序列变体，其中所述蛋白质：
a)与由SEQ ID NO：1所示的野生型Bet v2变应原相比，对IgE的反应性降低；和
b)通过至少一个在SEQ ID NO：1的位置Ser39、Lys45、Lys88或Lys89的Ser或Lys残基的取代从SEQ ID NO：1获得，其中所述Ser或Lys残基被取代为选自Ala、Thr、Ser、Gly、Glu和Asp的氨基酸残基。
2.根据权利要求1的低变应原性蛋白质，其选自SEQ ID NO：2-6。
3.核酸分子，其编码权利要求1或2的蛋白质。
4.根据权利要求3的核酸分子，其选自SEQ ID NO：8-12。
5.载体，其含有权利要求3或4的核酸分子。
6.宿主细胞，其含有权利要求5的载体。
7.药物组合物，其含有有效量的权利要求1或2的低变应原性蛋白质，以及可药用载体。
8.药物组合物，其含有有效量的权利要求1或2的低变应原性蛋白质，以及赋形剂。
9.根据权利要求7或8的组合物，其为疫苗形式。
10.权利要求1或2的低变应原性蛋白质在制备用于由来自垂枝桦物种的植物花粉导致的变应性疾病的预防性或治疗性治疗的药物组合物中的用途。
11.根据权利要求10的用途，其中所述变应性疾病选自支气管哮喘和变应性结膜炎。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI2007A001819 | 2007-09-19 | ||
| IT001819A ITMI20071819A1 (it) | 2007-09-19 | 2007-09-19 | Varianti ipoallergeniche dell'allergene maggiore bet v 2 di polline di betula verrucosa |
| PCT/EP2008/007726 WO2009036949A1 (en) | 2007-09-19 | 2008-09-16 | Hypoallergenic variants of the major allergen from betula verrucosa pollen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101861331A CN101861331A (zh) | 2010-10-13 |
| CN101861331B true CN101861331B (zh) | 2014-07-16 |
Family
ID=40029196
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200880116680.6A Active CN101861331B (zh) | 2007-09-19 | 2008-09-16 | 垂枝桦花粉主要变应原的低变应原性变体 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8591907B2 (zh) |
| EP (1) | EP2201031B1 (zh) |
| CN (1) | CN101861331B (zh) |
| AU (1) | AU2008300864B2 (zh) |
| CA (1) | CA2700047C (zh) |
| DK (1) | DK2201031T3 (zh) |
| EA (1) | EA019696B1 (zh) |
| ES (1) | ES2460573T3 (zh) |
| IT (1) | ITMI20071819A1 (zh) |
| MX (1) | MX2010002997A (zh) |
| WO (1) | WO2009036949A1 (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI20115374A0 (fi) * | 2011-04-18 | 2011-04-18 | Teknologian Tutkimuskeskus Vtt Oy | Uudet hypoallergeenit |
| RU2732013C1 (ru) * | 2019-12-11 | 2020-09-10 | Федеральное бюджетное учреждение науки "Государственный научный центр прикладной микробиологии и биотехнологии" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ПМБ) | Способ сенсибилизации планшета для иммуноферментного анализа нерастворимыми белковыми антигенами |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007073907A1 (en) * | 2005-12-29 | 2007-07-05 | Lofarma S.P.A. | Hypoallergenic variants of the major allergen from betula verrucosa pollen |
-
2007
- 2007-09-19 IT IT001819A patent/ITMI20071819A1/it unknown
-
2008
- 2008-09-16 CA CA2700047A patent/CA2700047C/en active Active
- 2008-09-16 US US12/679,207 patent/US8591907B2/en active Active
- 2008-09-16 ES ES08802256.1T patent/ES2460573T3/es active Active
- 2008-09-16 WO PCT/EP2008/007726 patent/WO2009036949A1/en active Application Filing
- 2008-09-16 AU AU2008300864A patent/AU2008300864B2/en active Active
- 2008-09-16 EP EP08802256.1A patent/EP2201031B1/en active Active
- 2008-09-16 CN CN200880116680.6A patent/CN101861331B/zh active Active
- 2008-09-16 EA EA201000360A patent/EA019696B1/ru not_active IP Right Cessation
- 2008-09-16 DK DK08802256.1T patent/DK2201031T3/da active
- 2008-09-16 MX MX2010002997A patent/MX2010002997A/es not_active Application Discontinuation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007073907A1 (en) * | 2005-12-29 | 2007-07-05 | Lofarma S.P.A. | Hypoallergenic variants of the major allergen from betula verrucosa pollen |
Non-Patent Citations (1)
| Title |
|---|
| Susanne Vrtala et al.High-Level Expression in Escherichia cloi and Purification of Recombinant Plant Profilins:comparison of IgE-Binding Capacity and Allergenic Activity.《BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS》.1996,第226卷(第1039期),第42-50页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2700047C (en) | 2017-01-17 |
| MX2010002997A (es) | 2010-06-01 |
| EP2201031A1 (en) | 2010-06-30 |
| ES2460573T3 (es) | 2014-05-13 |
| WO2009036949A1 (en) | 2009-03-26 |
| EA201000360A1 (ru) | 2010-10-29 |
| DK2201031T3 (da) | 2014-05-05 |
| ITMI20071819A1 (it) | 2009-03-20 |
| US20100310590A1 (en) | 2010-12-09 |
| EA019696B1 (ru) | 2014-05-30 |
| AU2008300864B2 (en) | 2014-02-27 |
| AU2008300864A1 (en) | 2009-03-26 |
| US8591907B2 (en) | 2013-11-26 |
| CA2700047A1 (en) | 2009-03-26 |
| CN101861331A (zh) | 2010-10-13 |
| EP2201031B1 (en) | 2014-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2014276484B2 (en) | Contiguous overlapping peptides for treatment of house dust mites allergy | |
| Asturias et al. | Engineering of major house dust mite allergens Der p 1 and Der p 2 for allergen‐specific immunotherapy | |
| CN103649315B (zh) | 低过敏原 | |
| AU2006331005B2 (en) | Hypoallergenic variants of the major allergen from Betula verrucosa pollen | |
| CN101861331B (zh) | 垂枝桦花粉主要变应原的低变应原性变体 | |
| Marazuela et al. | A non-allergenic Ole e 1-like protein from birch pollen as a tool to design hypoallergenic vaccine candidates | |
| Bonura et al. | A hybrid expressing genetically engineered major allergens of the Parietaria pollen as a tool for specific allergy vaccination | |
| Cromwell et al. | Clinical experience with recombinant molecules for allergy vaccination | |
| Marazuela et al. | Hypoallergenic mutants of Ole e 1, the major olive pollen allergen, as candidates for allergy vaccines | |
| EP2739308B1 (en) | Hypoallergenic variants of mal d 1, the major allergen from malus domestica | |
| Zhao et al. | Generation of a chimeric dust mite hypoallergen using DNA shuffling for application in allergen-specific immunotherapy | |
| Qin et al. | Construction by artificial intelligence and immunovalidation of hypoallergenic mite allergen Der f 36 vaccine | |
| EP2281836B1 (en) | Hybrid proteins from Parietaria judaica major allergens and uses thereof | |
| Bonura et al. | Genetic engineering of allergens for immunotherapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |